Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hepatitis

Free Subscription Articles published in Eur J Gastroenterol Hepatol Retrieve available abstracts of 37 articles: HTML format

Single Articles

March 2023
1. EBIK B, Cangul MS, Yalcin K
   What does quantitative HBsAg level mean in chronic hepatitis D infection?
   Eur J Gastroenterol Hepatol. 2023;35:320-326.
   PubMed     Abstract available
   
   
   
2. ZHANG P, Liu Z, Fan H, Shi T, et al
   Positive hepatitis B core antibody is associated with advanced fibrosis and mortality in nonalcoholic fatty liver disease.
   Eur J Gastroenterol Hepatol. 2023;35:294-301.
   PubMed     Abstract available
   
   
   February 2023
3. IDENO N, Nozaki A, Chuma M, Ogushi K, et al
   Fib-4 index predicts prognosis after achievement of sustained virologic response following direct-acting antiviral treatment in patients with hepatitis C virus infection.
   Eur J Gastroenterol Hepatol. 2023;35:219-226.
   PubMed     Abstract available
   
   
   
4. FENG Y, Yao N, Shi L, Zhu Y, et al
   Efficacy and safety of long-term postpartum antiviral therapy in hepatitis B virus-infected mothers receiving prophylactic tenofovir disoproxil fumarate treatment.
   Eur J Gastroenterol Hepatol. 2023;35:212-218.
   PubMed     Abstract available
   
   
   January 2023
5. ZHANG J, Zeng Q, Zhang P, Chen Y, et al
   Efficacy evaluation and prognostic risk factors analysis of precise hepatectomy in the treatment of intermediate and advanced hepatocellular carcinoma.
   Eur J Gastroenterol Hepatol. 2023;35:120-126.
   PubMed     Abstract available
   
   
   December 2022
6. LEE J, Chang JI, Jin YJ, Lee JH, et al
   Recurrence of hepatocellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection.
   Eur J Gastroenterol Hepatol. 2022 Dec 23. doi: 10.1097/MEG.0000000000002504.
   PubMed     Abstract available
   
   
   
7. LEE DU, Ponder R, Lee KJ, Yoo A, et al
   The nationwide trends in hospital admissions, deaths, and costs related to hepatitis C stratified by psychiatric disorders and substance use: an analysis of US hospitals between 2016 and 2019.
   Eur J Gastroenterol Hepatol. 2022 Dec 23. doi: 10.1097/MEG.0000000000002498.
   PubMed     Abstract available
   
   
   October 2022
8. YIBIRIN M, Hosry J, Yepez Guevara E, Granwehr BP, et al
   High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus.
   Eur J Gastroenterol Hepatol. 2022;34:1098-1101.
   PubMed     Abstract available
   
   
   September 2022
9. GARRIDO I, Liberal R, Peixoto A, Macedo G, et al
   "Long-term follow-up and prognosis of celiac hepatitis".
   Eur J Gastroenterol Hepatol. 2022 Sep 23. pii: 00042737-990000000-00077.
   PubMed     Abstract available
   
   
   July 2022
10. HUNYADY P, Herrmann E, Bojunga J, Friedrich-Rust M, et al
    Diagnostic value of a liver biopsy in patients with an acute liver failure or acute liver injury.
    Eur J Gastroenterol Hepatol. 2022;34:801-806.
    PubMed     Abstract available
    
    
    
11. PARIENTE A, Rosa I, Dharancy S, Hanslik B, et al
    Nonalcoholic fatty liver disease: opinions, population served, and management from a sample of French hepato(gastroentero)logists (PERSEPT study).
    Eur J Gastroenterol Hepatol. 2022;34:791-800.
    PubMed     Abstract available
    
    
    May 2022
12. SUN J, Yu X, Weng Z, Jin L, et al
    The impact of hepatotoxic drugs on the outcome of patients with acute deterioration of hepatitis B virus-related chronic disease.
    Eur J Gastroenterol Hepatol. 2022 May 5. pii: 00042737-990000000-00024.
    PubMed     Abstract available
    
    
    
13. DOFFOEL M, Tripon S, Ernwein F, Chaffraix F, et al
    Changes in the profile and therapeutic care of people who use drugs with HCV mono-infection: a retrospective study between 2015 and 2019 from a monocentric tertiary referent center in France.
    Eur J Gastroenterol Hepatol. 2022;34:560-566.
    PubMed     Abstract available
    
    
    April 2022
14. ALLGEIER J, Weber S, Todorova R, Neumann J, et al
    Acute liver injury following methylprednisolone pulse therapy: 13 cases from a prospectively collected cohort.
    Eur J Gastroenterol Hepatol. 2022;34:457-461.
    PubMed     Abstract available
    
    
    March 2022
15. TAHTASAKAL CA, Oncul A, Sevgi DY, Demirbas D, et al
    Fibrosis scores that can be used in follow-up of after direct-acting antiviral treatment: APRI, FIB-4, King score and GUCI.
    Eur J Gastroenterol Hepatol. 2022;34:308-315.
    PubMed     Abstract available
    
    
    February 2022
16. TOYODA H, Yasuda S, Shiota S, Kumada T, et al
    Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response.
    Eur J Gastroenterol Hepatol. 2022 Feb 14. pii: 00042737-900000000-97088.
    PubMed     Abstract available
    
    
    
17. HUANG X, Wang H, Zhang W, Gu E, et al
    Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment.
    Eur J Gastroenterol Hepatol. 2022 Feb 14. pii: 00042737-900000000-97084.
    PubMed     Abstract available
    
    
    December 2021
18. DOFFOEL M, Ernwein F, Chaffraix F, Haumesser L, et al
    Characteristics and care of chronic hepatitis C treated with direct-acting antivirals in migrants.
    Eur J Gastroenterol Hepatol. 2021 Dec 30. pii: 00042737-900000000-97102.
    PubMed     Abstract available
    
    
    
19. NG A
    Underdiagnosis of hepatitis C in the community: do not forget vulnerable populations.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    
    
    
    
20. NG A
    Hepatocellular carcinoma recurrence after directly-acting antiviral therapy: caution with hepatitis C.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    
    
    
    
21. BASSO M, Zago D, Pozzetto I, Parisi SG, et al
    Hepatitis C virus viral load distribution in the era of extended access to direct acting antivirals treatment: a real-life single center study.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    
    
    
    
22. KUMADA T, Toyoda H, Yasuda S, Ito T, et al
    Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available
    
    
    
23. HUBBARD A, Hirode G, Chitnis A, Wong R, et al
    Prevalence of hepatitis B surface antigen and hepatitis B core antibody among adults with latent tuberculosis infection.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available
    
    
    September 2021
24. EL KASSAS M, Abdeen N, Omran D, Alboraie M, et al
    Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 Sep 21. pii: 00042737-900000000-97142.
    PubMed     Abstract available
    
    
    
25. PATACCINI G, Pedrozo W, Mathet VL, Biglione MM, et al
    Prevalence of hepatitis D virus in blood donors with different hepatitis B virus markers of infection.
    Eur J Gastroenterol Hepatol. 2021;33:1229.
    PubMed    
    
    
    
26. PI B, Wang J, Tong Y, Yang Q, et al
    Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.
    Eur J Gastroenterol Hepatol. 2021 Sep 1. pii: 00042737-900000000-97150.
    PubMed     Abstract available
    
    
    July 2021
27. ALEM SA, Eletreby R, Abdellatif Z, Ramadan A, et al
    Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jul 6. pii: 00042737-900000000-97183.
    PubMed     Abstract available
    
    
    
28. EL RAY A, Fouad R, ElMakhzangy H, El Beshlawy M, et al
    Characterizing a cohort of Egyptian patients with acute-on-chronic liver failure.
    Eur J Gastroenterol Hepatol. 2021;33:1023-1028.
    PubMed     Abstract available
    
    
    June 2021
29. LIU X, Zhang J, Wei X, Duan Z, et al
    HBV-related acute-on-chronic liver failure with underlying chronic hepatitis has superior survival compared to cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 Jun 29. pii: 00042737-900000000-97185.
    PubMed     Abstract available
    
    
    
30. KHAN A, Sami K, Malik A, Mujtaba Bhinder M, et al
    Clinical outcomes and healthcare utilization of acute hepatitis A virus infection with acute kidney injury in hospitalized patients.
    Eur J Gastroenterol Hepatol. 2021 Jun 17. pii: 00042737-900000000-97190.
    PubMed     Abstract available
    
    
    May 2021
31. KOSEKLI MA
    Mean platelet volume and platelet to lymphocyte count ratio are associated with hepatitis B-related liver fibrosis.
    Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97205.
    PubMed     Abstract available
    
    
    
32. SHI K, Li P, Xue D, Liu Y, et al
    Neutrophil-lymphocyte ratio and the risk of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97202.
    PubMed     Abstract available
    
    
    April 2021
33. HAYES KN, Burkard T, Weiler S, Tadrous M, et al
    Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase.
    Eur J Gastroenterol Hepatol. 2021 Apr 21. pii: 00042737-900000000-97232.
    PubMed     Abstract available
    
    
    
34. EKMEN N, Can G, Can H
    Preliminary examination of the relations between disease stage, illness perceptions, coping strategies, and psychological morbidity in chronic hepatitis B and C guided by the Common-Sense Model of Illness.
    Eur J Gastroenterol Hepatol. 2021 Apr 16. pii: 00042737-900000000-97249.
    PubMed     Abstract available
    
    
    
35. YEO YH, Kam LY, Le MH, Jeong D, et al
    A population-based US study of hepatitis C diagnosis rate.
    Eur J Gastroenterol Hepatol. 2021 Apr 16. pii: 00042737-900000000-97245.
    PubMed     Abstract available
    
    
    
36. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
    Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication.
    Eur J Gastroenterol Hepatol. 2021 Apr 9. pii: 00042737-900000000-97256.
    PubMed     Abstract available
    
    
    January 2021
37. EL KASSAS M, Alboraie M, El-Sayed M, Elbehiry S, et al
    Effect of disease stage and treatment outcomes on the dynamics of liver functions during and after treatment of hepatitis C with directly acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jan 14. doi: 10.1097/MEG.0000000000002043.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: